Development of CAR-T cell therapy for B-ALL using a point-of-care approach

Recently approved by the FDA and European Medicines Agency, CAR-T cell therapy is a new treatment option for B-cell malignancies. Currently, CAR-T cells are manufactured in centralized facilities and face bottlenecks like complex scaling up, high costs, and logistic operations. These difficulties ar...

Descripción completa

Detalles Bibliográficos
Autores principales: de Macedo Abdo, Luiza, Barros, Luciana Rodrigues Carvalho, Saldanha Viegas, Mariana, Vieira Codeço Marques, Luisa, de Sousa Ferreira, Priscila, Chicaybam, Leonardo, Bonamino, Martín Hernán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185214/
https://www.ncbi.nlm.nih.gov/pubmed/32363126
http://dx.doi.org/10.1080/2162402X.2020.1752592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185214/
https://www.ncbi.nlm.nih.gov/pubmed/32363126
http://dx.doi.org/10.1080/2162402X.2020.1752592

Ejemplares similares